S100A7: A New Biomarker for Alzheimer's Disease
Author Information
Author(s): Qin Weiping, Ho Lap, Wang Jun, Peskind Elaine, Pasinetti Giulio Maria
Primary Institution: Mount Sinai School of Medicine
Hypothesis
Can S100A7 serve as a novel biomarker for early diagnosis of Alzheimer's disease?
Conclusion
S100A7 may be a promising biomarker for Alzheimer's disease, as its levels are elevated in the cerebrospinal fluid of patients with the condition.
Supporting Evidence
- S100A7 levels were significantly higher in the cerebrospinal fluid of Alzheimer's patients compared to controls.
- The study demonstrated that S100A7 promotes non-amyloidogenic α-secretase activity.
- Elevated S100A7 levels correlated with clinical dementia ratings in Alzheimer's patients.
- Transgenic mice expressing S100A7 showed increased α-secretase activity.
Takeaway
Scientists found a new protein called S100A7 that could help doctors tell if someone has Alzheimer's disease even before they show symptoms.
Methodology
The study used SELDI mass spectrometry to analyze cerebrospinal fluid samples from Alzheimer's patients and controls.
Potential Biases
Potential bias in sample selection and the reliance on specific biomarkers.
Limitations
The study primarily focused on a specific population and may not generalize to all demographics.
Participant Demographics
Participants included Alzheimer's patients and neurologically normal controls.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website